发布求助
文献互助 智能选刊 最新文献

Skin therapy letter最新文献

筛选
英文 中文
Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management. 表皮生长因子受体抑制剂:皮肤副作用及其处理。
Skin therapy letter Pub Date : 2017-09-01
S Monjazeb, J Wilson
{"title":"Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management.","authors":"S Monjazeb,&nbsp;J Wilson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Epidermal growth factor receptor (EGFR) inhibitors are part of an emerging class of anticancer medicines known as \"targeted therapy,\" which target pathways more specific to neoplastic proliferation than traditional chemotherapeutic agents. Adverse effects of such treatments are thought to be less severe, but can still be significant. Because EGFR is preferentially expressed in epithelial tissues, including the skin and hair follicle, cutaneous side effects of these agents are quite common. Not only can these toxicities severely affect patients' quality of life, but in some specific instances, they can be associated with increased response to therapy. It is of paramount importance that clinicians familiarize themselves with and understand the basic management of the range of cutaneous adverse effects caused by these drugs.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"22 5","pages":"5-7"},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35492512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vitamin B Derivative (Nicotinamide)Appears to Reduce Skin Cancer Risk. 维生素B衍生物(烟酰胺)似乎可以降低皮肤癌的风险。
Skin therapy letter Pub Date : 2017-09-01
S Nazarali, P Kuzel
{"title":"Vitamin B Derivative (Nicotinamide)Appears to Reduce Skin Cancer Risk.","authors":"S Nazarali,&nbsp;P Kuzel","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Nicotinamide, an amide form of vitamin B3, has shown the potential to treat a variety of dermatological conditions, including acne, rosacea, and atopic dermatitis. Recent studies have demonstrated the role of nicotinamide, in both topical and oral forms, as a chemopreventive agent against skin cancer. Its anti-carcinogenic role may be due to its ability to enhance DNA repair and prevent ultraviolet (UV)-induced immunosuppression, which is known to contribute to the progression of pre-malignant lesions. Furthermore, nicotinamide is a precursor of essential coenzymes for many important reactions in the body, including the production of nicotinamide adenine dinucleotide (NAD). NAD is a key coenzyme in the synthesis of adenosine triphosphate (ATP), which transports chemical energy within cells. Therefore, nicotinamide plays a significant role in supporting energy-dependent cellular processes, including DNA repair.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"22 5","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35338566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature. Secukinumab治疗银屑病和银屑病关节炎:文献综述
Skin therapy letter Pub Date : 2017-07-01
M Abrouk, J Gandy, M Nakamura, K Lee, M Brodsky, R Singh, H Zhu, B Farahnik, T Bhutani, J Koo
{"title":"Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature.","authors":"M Abrouk,&nbsp;J Gandy,&nbsp;M Nakamura,&nbsp;K Lee,&nbsp;M Brodsky,&nbsp;R Singh,&nbsp;H Zhu,&nbsp;B Farahnik,&nbsp;T Bhutani,&nbsp;J Koo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>While there are several commercially available treatment options for psoriasis and psoriatic arthritis, there remains a large number of individuals who are refractory to current modalities. In the recent past, there has been increasing evidence that interleukin (IL)-17 plays a vital role in the pathophysiology of psoriasis. Preclinical, phase II, and phase III studies of secukinumab (Cosentyx®) targeting IL-17 and its receptor have thus far proved to be promising. We reviewed the results of phase II and phase III clinical trials for secukinumab in the treatment of psoriasis and psoriatic arthritis. Only published studies were considered in the present review. We also performed an English language literature search from January 2003 to September 2015 using PubMed with any of the following key words: (secukinumab OR AIN457) AND (psoriasis OR psoriatic arthritis). In our review of the literature, seven phase III and five phase II clinical trials, as well as open-label extension studies with unpublished findings were found. Results from phase III clinical trials indicated secukinumab to be efficacious and safe for the treatment of psoriasis and psoriatic arthritis according to Psoriasis Area and Severity Index (PASI) and American College of Rheumatology (ACR) scores. The safety profile of this agent was similar across all studies, with the most frequently reported adverse events of nasopharyngitis, upper respiratory infections, headache, and injection site reaction. Secukinumab demonstrates rapid and robust clinical improvement accompanied by a favorable short- term safety profile. The results of the phase III trials continue to reinforce the theory that the IL-17 pathway is an essential target in psoriasis and psoriatic arthritis treatment. Additional extension studies of lower level evidence are needed to further understand the safety profile of the drug.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"22 4","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35189514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatitis B and C Viruses and Biologics. 乙型和丙型肝炎病毒和生物制剂。
Skin therapy letter Pub Date : 2017-07-01
P Grewal, R Sanghera
{"title":"Hepatitis B and C Viruses and Biologics.","authors":"P Grewal,&nbsp;R Sanghera","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hepatitis B virus (HBV) and hepatitis C virus (HCV) are common, worldwide viral illnesses that potentially impact the clinician's ability to manage patients with immunosuppressive medications such as biological therapy. In light of recent literature reviews, patients with HBV and HCV should be referred to a hepatologist or infectious disease expert prior to initiation of biological therapy.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"22 4","pages":"7-9"},"PeriodicalIF":0.0,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35190409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psoriasis, Depression, and Suicidality. 牛皮癣、抑郁症和自杀倾向。
Skin therapy letter Pub Date : 2017-05-01
M N Nicholas, M Gooderham
{"title":"Psoriasis, Depression, and Suicidality.","authors":"M N Nicholas,&nbsp;M Gooderham","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Psoriasis is a chronic condition that affects the well-being and quality of life of patients. The disease is associated with an increased risk of depression and suicidality, which may not be fully understood by the general population. It is crucial to understand the effect this disease has on mental health and determine risk factors that may help identify patients who are susceptible to depression and suicidality. Risk factors discussed in this article include age, gender, and severity of disease in psoriasis patients. Of these, age and severity of disease are significant with a clear association of increased depression and suicidality found in patients who are younger or have more severe disease. Although there is evidence that psoriasis treatments can improve both disease and associated depression symptoms, there are high rates of undertreatment. By identifying high-risk psoriasis patients, dermatologists can aim for optimal treatment of the disease and thus help alleviate the associated psychiatric burden.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"22 3","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34979334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Skin Care in Optimizing Treatment of Acne and Rosacea. 皮肤护理在痤疮和酒渣鼻优化治疗中的作用。
Skin therapy letter Pub Date : 2017-05-01
C Zip
{"title":"The Role of Skin Care in Optimizing Treatment of Acne and Rosacea.","authors":"C Zip","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A triad approach to the treatment of acne and rosacea has been recommended. This integrated management approach includes patient education, selection of therapeutic agents, and initiation of an appropriate skin care regime. Proper skin care in patients undergoing treatment of both acne and rosacea includes use of products formulated for sensitive skin that cleanse, moisturize and photoprotect the skin. Both acne and rosacea are associated with epidermal barrier dysfunction, which can be mitigated by suitable skin care practices. Appropriate skin care recommendations for patients with acne and rosacea will be discussed.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"22 3","pages":"5-7"},"PeriodicalIF":0.0,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34986672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis. 托法替尼治疗类风湿性关节炎和慢性斑块型银屑病。
Skin therapy letter Pub Date : 2017-03-01
A K Gupta, M Cernea, C W Lynde
{"title":"Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.","authors":"A K Gupta,&nbsp;M Cernea,&nbsp;C W Lynde","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tofacitinib is an oral immunosuppressant approved for the treatment of rheumatoid arthritis (RA) and is currently undergoing investigation (Phase III trials) for treating chronic plaque psoriasis. Tofacitinib inhibits Janus kinases (JAKs), which are essential for the signaling of multiple inflammatory pathways and have been implicated in the pathogenesis of RA and psoriasis. The efficacy and safety of tofacitinib in the treatment of RA and psoriasis have been demonstrated in Phase III trials. Across all studies, the efficacy of tofacitinib in alleviating symptoms of RA and psoriasis were superior to placebo. Moreover, treatment was generally well-tolerated, with the most frequently reported adverse events, for both RA and psoriasis, being nasopharyngitis and upper respiratory tract infection. As such, tofacitinib proves to be an effective therapeutic option for RA and a promising new therapy for psoriasis.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"22 2","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34843948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis. IL-23抑制剂Guselkumab治疗中重度斑块性银屑病的研究进展
Skin therapy letter Pub Date : 2017-03-01
Z Nawas, M Hatch, E Ramos, M Liu, Y Tong, A Peranteau, S Tyring
{"title":"A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis.","authors":"Z Nawas,&nbsp;M Hatch,&nbsp;E Ramos,&nbsp;M Liu,&nbsp;Y Tong,&nbsp;A Peranteau,&nbsp;S Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Psoriasis is a chronic inflammatory skin disorder that affects 2% of the population. Evidence suggests that interleukin (IL)-23 plays a pivotal role in the pathogenesis of psoriasis. Guselkumab is a subcutaneously administered, humanized anti-IL23 monoclonal antibody indicated for the treatment of moderate-to-severe plaque psoriasis. Data from Phase I-III trials in this patient population reveal that guselkumab has proven to be superior to placebo or adalimumab based on achieving a Psoriasis Area and Severity Index (PASI) 90% reduction, or a static Physician Global Assessment (sPGA) score of 0 or 1 from baseline. This article reviews the current status of guselkumab as a therapy for moderate-to-severe plaque psoriasis.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"22 2","pages":"8-10"},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34843949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sodium Deoxycholate for Submental Contouring. 去氧胆酸钠用于颏下轮廓。
Skin therapy letter Pub Date : 2016-09-01
S Humphrey, K Beleznay, J D A Beleznay
{"title":"Sodium Deoxycholate for Submental Contouring.","authors":"S Humphrey,&nbsp;K Beleznay,&nbsp;J D A Beleznay","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The chin and jaw line are integral parts of an individual's aesthetic profile, and the presence of submental fat detracts from this and can lead to displeasure with one's facial appearance. While liposuction and cosmetic surgery are regarded as the gold standard in treating submental fat, surgical intervention is not appealing to all patients and has potential surgical complications including longer recovery, and contour irregularities. Despite ample advances in aesthetic medicine to enhance the appearance of the face, very little is available in non-invasive options to reduce submental fat that has been supported by robust evidence. ATX-101, a proprietary formulation of deoxycholic acid that is synthetically derived, has been extensively explored in a vigorous clinical development program that has established the safety and efficacy of the injectable. It has recently received approval by regulatory authorities in Canada (Belkyra™) and the US (Kybella®) for the treatment of submental fat. </p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"21 5","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34423980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rituximab: Uses in Dermatology. 利妥昔单抗:用于皮肤病学。
Skin therapy letter Pub Date : 2016-09-01
K Gleghorn, J Wilson, M Wilkerson
{"title":"Rituximab: Uses in Dermatology.","authors":"K Gleghorn,&nbsp;J Wilson,&nbsp;M Wilkerson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Chronic graft-versus-host disease and pemphigus vulgaris are two of the most promising indications for off-label use of rituximab. It is a generally safe alternative that should be considered when traditional therapy with corticosteroids or immunosuppressants has failed or caused significant intolerance. Currently, rituximab is only FDA-approved for treatment of follicular and diffuse large B-cell non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, granulomatosis with polyangiitis (formerly Wegener's granulomatosis) and microscopic polyangiitis. Herein, off-label uses of rituximab and its efficacy in the treatment of cutaneous diseases are reviewed. </p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"21 5","pages":"5-7"},"PeriodicalIF":0.0,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34423981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信